Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Article Details

Citation

Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K

Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27.

PubMed ID
29637542 [ View in PubMed
]
Abstract

Current formulations of combined oral contraceptives (COC) containing ethinylestradiol (EE) have

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
EthinylestradiolCytochrome P450 1A2ProteinHumans
Unknown
Substrate
Details
EthinylestradiolCytochrome P450 2C8ProteinHumans
Unknown
Substrate
Inhibitor
Details
EthinylestradiolCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Details
EthinylestradiolCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Details
EthinylestradiolUDP-glucuronosyltransferase 1-1ProteinHumans
No
Substrate
Inducer
Details
Drug Reactions
Reaction
Details
Details
Details
Details
Details
Details